株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

がん免疫療法の世界市場 - 成長、動向、予測(2019年~2024年)

Cancer Immunotherapy Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 911946
出版日 ページ情報 英文 115 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
がん免疫療法の世界市場 - 成長、動向、予測(2019年~2024年) Cancer Immunotherapy Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年09月01日 ページ情報: 英文 115 Pages
概要

世界のがん免疫療法市場は、2019年から2024年にかけて12.2%のCAGRで成長すると予測されています。研究開発活動の増加や、新たな治療法の有効性の向上、がんの有病率の上昇などが当市場の成長を促進しています。

当レポートでは、世界のがん免疫療法市場を調査し、市場の概要、治療タイプ・用途・エンドユーザー・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場の成長要因
    • 研究開発活動の増加
    • 新しい治療法の有効性の向上
    • がんの有病率の上昇
  • 市場の阻害要因
    • 開発コストの高さ
    • 厳格規制
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第5章 市場セグメンテーション

  • 治療タイプ別
    • モノクローナル抗体
    • がんワクチン
    • 免疫調節薬
    • 免疫チェックポイント阻害剤
    • その他
  • 用途別
    • 前立腺がん
    • 乳がん
    • 皮膚がん
    • 肺がん
    • その他(膵がん、大腸がん、卵巣がんなど)
  • エンドユーザー別
    • 病院・診療所
    • がん研究センター
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Amgen Inc.
    • アステラス製薬
    • AstraZeneca
    • Bayer AG
    • Bristol-Myers Squibb
    • Eli Lilly and Co.
    • F. Hoffman La Roche
    • Merck and Co.
    • Novartis
    • OSE Immunotherapeutics

第7章 市場機会および将来動向

目次
Product Code: 66758

Market Overview

Cancer Immunotherapy Market is expected to witness a CAGR of 12.2% during the forecast period. Certain factors that are driving the market are R&D activities, increasing effectivity and accuracy of newer therapies, growing prevalence of cancer.

The incidence of cancer is increasing significantly and has been the major factor for the growth of the cancer immunotherapy market. Cancer damages the immune system, as cancer cells produce the self-antigen. The cancer immunotherapy plays a vital role in the maintenance of the immune system, and it targets the infectious agents that may cause cancer through the production of the antibodies. Cancer Immunotherapy is considered as new therapy and is not popular compared to the other alternative therapeutic drugs. However, cancer immunotherapy has shown great potential over the past few years. Also, with healthcare physicians looking for the alternative therapies due to the huge burden of cancer cases and side effects of the present therapies, the market of cancer immunotherapy is expected to grow with a high growth rate during the forecast period.

However, in the expanding market for medical therapies, there are stringent regulatory policies in place to ensure the safety of therapies. The FDA review process takes twice as much as time as European regulatory commissions' review bodies. The presence of stringent regulations is dampening the innovation in the market and hindering the growth of this market.

Scope of the Report

Immunotherapy is a treatment that uses certain parts of a person's immune system to fight diseases such as cancer. This can be done either by stimulating one's own immune system to work harder and smarter to attack cancer cells, or by giving one immune system components, such as man-made immune system proteins.

Key Market Trends

Cancer Vaccines are Expected to Show Lucrative Growth Opportunity in the Therapy Type Segment

Various advancements are taking place in the field of cancer vaccines owing to the ongoing research studies all across the globe. Cancer vaccines can majorly be classified into two types i.e. preventive vaccines and therapeutic vaccines. Preventive cancer vaccine or prophylactic vaccines are the vaccines that are intended to prevent the development of cancer in healthy people. These vaccines work by preventing infectious agents that cause or contribute to the development of cancer. These vaccines are similar to a traditional vaccine that helps in preventing infectious diseases, such as polio and measles, by protecting the body against infections. Most of the preventive vaccines stimulate the production of antibodies, which bind to the specifically targeted microbes and block their ability to cause infection.

North America Dominates the Market and Expected to do Same in the Forecasted Period

This is due to the high prevalence of cancer, along with developed healthcare infrastructure in the region. According to the National Cancer Institute, preventive cancer vaccines were approved to treat cancers caused by the use of vaccines, namely Human papillomavirus (HPV) vaccines and the Hepatitis B virus (HBV). However, there are many other immunotherapies that were approved by the FDA for the prevention of cancer. In April 2010, the first cancer treatment vaccine, called sipuleucel-T (Provenge), was approved by the FDA. This vaccine was approved for use in men with metastatic prostate cancer. It was designed to stimulate an immune response to prostatic acid phosphatase (PAP), which is an antigen found in most prostate cancer cells. Moreover, in October 2015, the first oncolytic virus therapy, called talimogene laherparepvec (T-VEC, or Imlygic), was also approved by the FDA. This vaccine is used for the treatment of metastatic melanoma that cannot be surgically removed.

Competitive Landscape

The Cancer Immunotherapy market is highly competitive and consists of a few major players. Companies like Amgen Inc., Astellas Pharma, Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb, Eli Lilly and Co., F. Hoffman La Roche, Merck and Co., Novartis, OSE Immunotherapeutics, among others, hold the substantial market share in the Cancer Immunotherapy market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising R&D Activities
    • 4.2.2 Increasing Effectivity and Accuracy of Newer Therapies
    • 4.2.3 Growing Prevalence of Cancer
  • 4.3 Market Restraints
    • 4.3.1 High Cost Coupled with Expensive Development
    • 4.3.2 Stringent Regulatory Factors
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Therapy Type
    • 5.1.1 Monoclonal Antibodies
    • 5.1.2 Cancer Vaccines
    • 5.1.3 Immunomodulators
    • 5.1.4 Immune Check Point Inhibitors
    • 5.1.5 Others
  • 5.2 Application
    • 5.2.1 Prostate Cancer
    • 5.2.2 Breast Cancer
    • 5.2.3 Skin Cancer
    • 5.2.4 Lung Cancer
    • 5.2.5 Others (Pancreatic, Colorectal, Ovarian, etc.)
  • 5.3 End Users
    • 5.3.1 Hospitals and Clinics
    • 5.3.2 Cancer Research Centers
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Amgen Inc.
    • 6.1.2 Astellas Pharma, Inc.
    • 6.1.3 AstraZeneca
    • 6.1.4 Bayer AG
    • 6.1.5 Bristol-Myers Squibb
    • 6.1.6 Eli Lilly and Co.
    • 6.1.7 F. Hoffman La Roche
    • 6.1.8 Merck and Co.
    • 6.1.9 Novartis
    • 6.1.10 OSE Immunotherapeutics

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top